0 CHECKOUT

Malignant Glioma - Pipeline Review, H1 2015

  • ID: 3099725
  • January 2015
  • 87 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advantagene, Inc.
  • Eli Lilly and Company
  • iDD biotech SAS
  • Merck & Co., Inc.
  • Nuo Therapeutics, Inc.
  • Orbus Therapeutics, Inc.
  • MORE

Malignant Glioma - Pipeline Review, H1 2015

Summary

This, ‘Malignant Glioma - Pipeline Review, H1 2015’, provides an overview of the Malignant Glioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advantagene, Inc.
  • Eli Lilly and Company
  • iDD biotech SAS
  • Merck & Co., Inc.
  • Nuo Therapeutics, Inc.
  • Orbus Therapeutics, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Malignant Glioma Overview
Therapeutics Development
Pipeline Products for Malignant Glioma - Overview
Pipeline Products for Malignant Glioma - Comparative Analysis
Malignant Glioma - Therapeutics under Development by Companies
Malignant Glioma - Therapeutics under Investigation by Universities/Institutes
Malignant Glioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Malignant Glioma - Products under Development by Companies
Malignant Glioma - Products under Investigation by Universities/Institutes
Malignant Glioma - Companies Involved in Therapeutics Development
Advantagene, Inc.
Eli Lilly and Company
iDD biotech SAS
Lipopharma Therapeutics SL
Merck & Co., Inc.
Nuo Therapeutics, Inc.
Orbus Therapeutics, Inc.
Sanofi
Stemline Therapeutics, Inc.
ZIOPHARM Oncology, Inc.
Malignant Glioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ad-RTS-IL-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALD-451 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Malignant Gliomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eflornithine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
galunisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GliAtak - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDD-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LD-224 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
marizomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minerval - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target Survivin for Malignant Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
voxtalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Malignant Glioma - Recent Pipeline Updates
Malignant Glioma - Dormant Projects
Malignant Glioma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Malignant Glioma, H1 2015
Number of Products under Development for Malignant Glioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Malignant Glioma - Pipeline by Advantagene, Inc., H1 2015
Malignant Glioma - Pipeline by Eli Lilly and Company, H1 2015
Malignant Glioma - Pipeline by iDD biotech SAS, H1 2015
Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H1 2015
Malignant Glioma - Pipeline by Merck & Co., Inc., H1 2015
Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H1 2015
Malignant Glioma - Pipeline by Orbus Therapeutics, Inc., H1 2015
Malignant Glioma - Pipeline by Sanofi, H1 2015
Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H1 2015
Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Malignant Glioma Therapeutics - Recent Pipeline Updates, H1 2015
Malignant Glioma - Dormant Projects, H1 2015
Malignant Glioma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Malignant Glioma, H1 2015
Number of Products under Development for Malignant Glioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Advantagene, Inc.
Eli Lilly and Company
iDD biotech SAS
Lipopharma Therapeutics SL
Merck & Co., Inc.
Nuo Therapeutics, Inc.
Orbus Therapeutics, Inc.
Sanofi
Stemline Therapeutics, Inc.
ZIOPHARM Oncology, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Qiagen N.V.
  • Elekta AB
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb
  • Genentech, Inc.